KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $127.2 million.

  • Halozyme Therapeutics' Shares Outstanding (Weighted Average) fell 7.67% to $117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.0 million, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $127.2 million for FY2024, which is 3.69% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $127.2 million for FY2024, which was down 3.69% from $132.1 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $140.8 million for FY2021, and its period low was $127.2 million during FY2024.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $131.5 million, with a median of $132.1 million in 2023.
  • As far as peak fluctuations go, Halozyme Therapeutics' Shares Outstanding (Weighted Average) declined by 7.75% in 2020, and later increased by 4.15% in 2021.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Shares Outstanding (Weighted Average) stood at $135.2 million in 2020, then rose by 4.15% to $140.8 million in 2021, then dropped by 3.96% to $135.2 million in 2022, then fell by 2.30% to $132.1 million in 2023, then declined by 3.69% to $127.2 million in 2024.